|
Characteristics
|
Total (N = 819)
|
|---|
|
N (%)
|
|---|
|
Age (in years)
|
|
<50
|
348 (42.5)
|
|
≥50
|
471 (57.5)
|
|
NPI score
|
|
Median (range)
|
5.52 (3.0–9.0)
|
|
Treatment group
|
|
E-CMF
|
123 (15.0)
|
|
E-T-CMF
|
392 (47.9)
|
|
ET-CMF
|
304 (37.1)
|
|
Menopausal status
|
|
Premenopausal
|
375 (45.8)
|
|
Postmenopausal
|
444 (54.2)
|
|
Breast surgery
|
|
Modified radical mastectomy
|
579 (70.7)
|
|
Breast-conserving surgery
|
240 (29.3)
|
|
ER/PgR status
|
|
Negative
|
165 (21.7)
|
|
Positive
|
596 (78.3)
|
|
Histological grade
|
|
I–II
|
406 (49.6)
|
|
III–Undifferentiated
|
413 (50.4)
|
|
Tumor size (cm)
|
|
≤2
|
181 (22.8)
|
|
2–5
|
517 (65.2)
|
|
>5
|
95 (12.0)
|
|
Positive lymph nodes
|
|
1–3 nodes
|
331 (40.5)
|
|
≥4 nodes
|
487 (59.5)
|
|
Adjuvant radiation therapy
|
|
No
|
184 (23.2)
|
|
Yes
|
609 (76.8)
|
|
Adjuvant hormonal therapy
|
|
No
|
154 (18.9)
|
|
Yes
|
661 (81.1)
|
|
Bone metastases
|
|
No
|
711 (88.4)
|
|
Yes
|
93 (11.6)
|
|
HER2 status
|
|
Negative
|
593 (76.5)
|
|
Positive
|
182 (23.5)
|
|
Ki67 protein expression
|
|
Low (<20%)
|
367 (44.8)
|
|
High (≥20%)
|
452 (55.2)
|
|
Subtypes
|
|
Luminal A
|
245 (32.3)
|
|
Luminal B
|
248 (32.8)
|
|
Luminal-HER2
|
99 (13.1)
|
|
HER2-enriched
|
79 (10.4)
|
|
Triple-negative
|
86 (11.4)
|
|
OPN mRNA expression
|
|
Low (<50th percentile)
|
407 (50.0)
|
|
High (≥50th percentile)
|
407 (50.0)
|
|
OPN protein expression
|
|
Low (0–4 Allred score)
|
59 (10.8)
|
|
High (5–8 Allred score)
|
487 (89.2)
|
